Lorilee Sutter
Rheumatology · Palm Springs, CANPI 1114906435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 33.2% of the total.
Across 142 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$609
- UCB, Inc.$457
- GSK$405
- Pfizer$262
- Radius Health, Inc.$172
- plus $529 from 9 others
What the payments were for
- Consulting fees$401%
- Food & beverage$3,51797%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $1,211 |
| Amgen | 35 | $609 |
| UCB, Inc. | 12 | $457 |
| GSK | 20 | $405 |
| Pfizer | 15 | $262 |
| Radius Health, Inc. | 5 | $172 |
| Boehringer Ingelheim | 4 | $155 |
| Lilly USA, LLC | 2 | $145 |
| Novartis | 4 | $87 |
| AstraZeneca | 2 | $32 |
| Fresenius Kabi USA, LLC | 1 | $29 |
| Sanofi | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,645 in reported general payments places this provider in the 55th percentile of 808 rheumatology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 45 | $151,963 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 47 | $116,689 |
| EvenityRomosozumab-Aqqg | 29 | $72,202 |
| RinvoqUpadacitinib | 11 | $69,965 |
| ProliaDenosumab | 17 | $29,960 |
| Leflunomide | 44 | $2,582 |
| Hydroxychloroquine Sulfate | 41 | $2,045 |
| Mycophenolate Mofetil | 21 | $1,896 |
| Colchicine | 16 | $1,358 |
| MethotrexateMethotrexate Sodium | 137 | $1,290 |
| Celecoxib | 24 | $1,280 |
| Cevimeline Hcl | 11 | $866 |
| Bupropion Hcl SrBupropion Hcl | 40 | $665 |
| Prednisone | 115 | $661 |
| Gabapentin | 37 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEvenity (2 Syringes), Evenity, Prolia | $609 | $218,85193 claims |
| AbbVieRinvoq | $1,211 | $69,96511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 808 rheumatology providers in California.
Other rheumatology in Palm Springs
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.